BTIG Research Reiterates “Buy” Rating for Apogee Therapeutics (NASDAQ:APGE)

Apogee Therapeutics (NASDAQ:APGE)‘s stock had its “buy” rating reaffirmed by research analysts at BTIG Research in a note issued to investors on Monday,Benzinga reports. They presently have a $137.00 price target on the stock. BTIG Research’s price objective indicates a potential upside of 70.03% from the company’s previous close.

Several other research analysts have also commented on the company. Stifel Nicolaus set a $133.00 price objective on Apogee Therapeutics in a report on Tuesday, January 6th. Citigroup reaffirmed a “buy” rating on shares of Apogee Therapeutics in a research note on Sunday, January 25th. Wedbush lifted their target price on shares of Apogee Therapeutics from $90.00 to $95.00 and gave the company an “outperform” rating in a research report on Tuesday, March 3rd. Jefferies Financial Group reissued a “buy” rating and issued a $95.00 price target on shares of Apogee Therapeutics in a report on Monday, February 2nd. Finally, Truist Financial assumed coverage on shares of Apogee Therapeutics in a research report on Tuesday, March 17th. They set a “hold” rating and a $83.00 price objective on the stock. Three equities research analysts have rated the stock with a Strong Buy rating, eight have issued a Buy rating, four have given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $103.92.

Apogee Therapeutics Stock Up 22.0%

NASDAQ:APGE traded up $14.54 during trading hours on Monday, hitting $80.58. 1,844,019 shares of the company’s stock traded hands, compared to its average volume of 992,418. Apogee Therapeutics has a 52 week low of $26.20 and a 52 week high of $84.56. The business’s fifty day simple moving average is $71.25 and its two-hundred day simple moving average is $63.40. The firm has a market cap of $5.60 billion, a P/E ratio of -19.13 and a beta of 1.39.

Apogee Therapeutics (NASDAQ:APGE) last announced its earnings results on Monday, March 2nd. The company reported ($1.03) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.05) by $0.02. On average, analysts expect that Apogee Therapeutics will post -3.09 EPS for the current year.

Insider Activity at Apogee Therapeutics

In related news, CEO Michael Thomas Henderson sold 20,000 shares of the business’s stock in a transaction that occurred on Wednesday, March 11th. The stock was sold at an average price of $74.78, for a total value of $1,495,600.00. Following the completion of the sale, the chief executive officer owned 1,152,987 shares in the company, valued at $86,220,367.86. The trade was a 1.71% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, Director Fairmount Funds Management Llc sold 1,750,000 shares of the company’s stock in a transaction that occurred on Thursday, January 22nd. The stock was sold at an average price of $76.30, for a total value of $133,525,000.00. Following the completion of the sale, the director directly owned 298,647 shares of the company’s stock, valued at approximately $22,786,766.10. This represents a 85.42% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last three months, insiders have sold 1,839,700 shares of company stock valued at $140,118,083. Corporate insiders own 42.77% of the company’s stock.

Institutional Investors Weigh In On Apogee Therapeutics

A number of hedge funds have recently made changes to their positions in APGE. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its stake in shares of Apogee Therapeutics by 2.9% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 24,529 shares of the company’s stock valued at $921,000 after purchasing an additional 694 shares in the last quarter. Millennium Management LLC raised its position in Apogee Therapeutics by 100.0% in the 1st quarter. Millennium Management LLC now owns 260,335 shares of the company’s stock worth $9,726,000 after purchasing an additional 130,164 shares during the period. Creative Planning purchased a new position in Apogee Therapeutics in the 2nd quarter worth $392,000. Handelsbanken Fonder AB lifted its stake in Apogee Therapeutics by 13.3% in the second quarter. Handelsbanken Fonder AB now owns 8,500 shares of the company’s stock worth $369,000 after purchasing an additional 1,000 shares during the last quarter. Finally, Legal & General Group Plc boosted its position in Apogee Therapeutics by 7.4% during the second quarter. Legal & General Group Plc now owns 27,689 shares of the company’s stock valued at $1,203,000 after buying an additional 1,907 shares during the period. 79.04% of the stock is currently owned by institutional investors.

Trending Headlines about Apogee Therapeutics

Here are the key news stories impacting Apogee Therapeutics this week:

• Positive Sentiment: Phase 2 Part A (APEX) 52‑week data showed durable maintenance and deepening of responses for zumilokibart with both every‑3‑month and every‑6‑month dosing — including 75% and 85% of patients maintaining EASI‑75, and 86% and 78% maintaining vIGA 0/1 — supporting efficacy and an attractive infrequent‑dosing profile. Apogee Therapeutics Announces Positive Phase 2 Part A 52‑Week Data
• Positive Sentiment: Financial and news outlets are reporting the positive readout and attributing the stock move to the data, increasing investor attention and trading volume. Coverage highlights the durable responses and convenience of 3‑ and 6‑month dosing. Apogee Therapeutics Stock Rallies On Encouraging Eczema Drug Data Readout
• Positive Sentiment: Apogee scheduled a conference call/webcast to present the Part A 52‑week results (held March 23), providing management commentary and Q&A that can clarify safety, responder durability, and next steps — a potential near‑term catalyst for guidance or program timing. Apogee Therapeutics to Host Conference Call
• Neutral Sentiment: Analysts and commentators are re‑examining valuation after recent share weakness; while the data de‑risks the program, Apogee remains a clinical‑stage biotech with no commercial revenue — valuation and upside will depend on Phase 2 Part B, safety details, and regulatory path. A Look At Apogee Therapeutics (APGE) Valuation After Recent Share Price Weakness

About Apogee Therapeutics

Apogee Therapeutics, Inc is a clinical-stage biotechnology company dedicated to the discovery and development of novel small molecule therapeutics that selectively target the nuclear receptor RORγt, a master regulator of T cell-driven inflammatory pathways. By modulating RORγt activity, Apogee aims to offer an oral treatment option for patients with autoimmune and inflammatory skin disorders.

The company’s lead candidate, APG-157, is an oral RORγt inverse agonist currently undergoing early-stage clinical evaluation for moderate to severe plaque psoriasis.